MRI联合CDK4、Ki-67对早期宫颈癌淋巴结转移的预测价值

游会婷; 晋茂生; 刘健

doi:10.16766/j.cnki.issn.1674-4152.003318

MRI联合CDK4、Ki-67对早期宫颈癌淋巴结转移的预测价值

doi: 10.16766/j.cnki.issn.1674-4152.003318

1.
蚌埠医学院第一附属医院妇产科，安徽蚌埠 233004
2.
蚌埠医学院第一附属医院肿瘤妇科

基金项目:

安徽省高校科学研究项目 KJ2019A0363

详细信息

通讯作者:
晋茂生, E-mail: 676926817@qq.com

中图分类号: R737.33 R730.4
计量
- 文章访问数: 304
- HTML全文浏览量: 92
- PDF下载量: 26
- 被引次数: 0
出版历程
- 收稿日期: 2023-09-02
- 网络出版日期: 2024-03-09

Predictive value of MRI combined with CDK4 and Ki-67 for lymph node metastasis in early cervical cancer

1.
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

摘要

摘要: 目的探讨MRI联合细胞周期蛋白依赖性激酶(CDK4)、Ki-67对早期宫颈癌淋巴结转移的预测价值。方法选取2020年12月—2022年10月在蚌埠医学院第一附属医院首次行宫颈癌根治术的患者101例，根据病理结果将其分为淋巴结转移组(LNM组)30例与非淋巴结转移组(NLNM组)71例。比较2组患者MRI淋巴结转移、肿瘤直径、间质浸润深度、宫旁及阴道受累情况、CDK4、Ki-67表达情况以及一般资料，多指标分析联合对早期宫颈癌淋巴结转移的预测价值。结果单因素分析显示：2组肿瘤直径、鳞状细胞癌抗原(SCC-Ag)、间质浸润深度、脉管浸润、MRI淋巴结转移、CDK4及Ki-67比较差异均有统计学意义(P＜0.05)。Logistic回归分析显示：肿瘤直径、SCC-Ag、间质浸润深度、Ki-67均为淋巴结转移的独立影响因素(P＜0.05)。CDK4、Ki-67、SCC-Ag及MRI的曲线下面积(AUC)分别为0.637、0.740、0.792、0.857；灵敏度分别为0.967、0.833、0.700、0.967, 特异度分别为0.282、0.592、0.845、0.634；SCC-Ag的最佳截断值为3.60 ng/mL, 约登指数为0.545；MRI联合SCC-Ag预测盆腔淋巴结转移的AUC为0.890，小于MRI联合CDK4、Ki-67联合诊断评估盆腔淋巴结转移的AUC(0.917)，小于多指标联合预测盆腔淋巴结转移的AUC(0.943，P＜0.05)。结论 MRI单独用于诊断宫颈癌淋巴结转移的灵敏度较低，CDK4的灵敏度较高但是不具有特异性，当MRI、CDK4、Ki-67三者联合时灵敏度和特异度均有明显提高，对于术前淋巴结转移具有预测价值。
- 宫颈癌 /
- 淋巴结转移 /
- 影像学 /
- 细胞周期蛋白依赖性激酶4 /
- Ki-67
Abstract: Objective To explore the predictive value of MRI combined with Cyclin-dependent kinase 4 (CDK4) and Ki-67 in predicting lymph node metastasis of early cervical cancer. Methods A total of 101 patients who were diagnosed with cervical cancer for the first time and underwent radical cervical cancer resection in the First Affiliated Hospital of Bengbu Medical College from December 2020 to October 2022 were selected and divided into lymphatic metastasis group (LNM group, n=30) and non-lymphatic metastasis group (NLNM group, n=71) according to pathological results. MRI lymph node metastasis, tumor diameter, stromal infiltration depth, uterine vagina involvement, CDK4, Ki-67 expression and general data were compared between the two groups. The prediction value of lymph node metastasis in early cervical cancer was analyzed. Results Single factor results showed that there were statistically significant differences in tumor diameter, SCC-Ag, depth of interstitial invasion, vascular invasion, MRI lymph node metastasis, CDK4 and Ki-67 (P < 0.05). Logistic regression analysis results showed that tumor diameter, squamous cell carcinoma antigen (SCC-Ag), depth of interstitial invasion and Ki-67 were independent risk factors for lymph node metastasis (P < 0.05). The area under the curve (AUC) of CDK4, Ki-67, SCC-Ag and MRI were 0.637, 0.740, 0.792 and 0.857, respectively. The sensitivity were 0.967, 0.833, 0.700, 0.967 and the specificity were 0.282, 0.592, 0.845, 0.634 respectively. The optimal cutoff value of SCC-Ag was 3.6 ng/mL, and the Jorden index was 0.545. The AUC of MRI combined with SCC-Ag in predicting pelvic lymph node metastasis was 0.890, which was smaller than the AUC of MRI combined with CDK4 and Ki-67 in evaluating pelvic lymph node metastasis (0.917), and smaller than the AUC of multiple indicators combined in predicting pelvic lymph node metastasis (0.943, P < 0.05). Conclusion MRI alone has low sensitivity in the diagnosis of cervical cancer lymph node metastasis, while CDK4 has high sensitivity but no specificity. When MRI, CDK4 and Ki-67 are combined, both sensitivity and specificity are significantly improved, which has predictive value for preoperative lymph node metastasis.
- Cervical cancer /
- Lymph node metastasis /
- Imaging /
- Cyclin-dependent kinase 4 /
- Ki-67

HTML全文

图 1 2组CDK4、Ki-67表达情况(免疫组化，×200)

注：A为CDK4在淋巴结转移组中的表达；B为CDK4在非淋巴结转移组中的表达；C为Ki-67在淋巴结转移组中的表达；D为Ki-67在非淋巴结转移组中的表达。

Figure 1. Immunohistochemical expression of CDK4 and KI-67 in the two group (Immunohistochemistry, ×200)

下载: 全尺寸图片幻灯片

图 2 各指标及多指标联合诊断宫颈癌淋巴结转移的ROC曲线

Figure 2. Receiver operating characteristic curve of each index and multi-index combination

下载: 全尺寸图片幻灯片

表 1 影响盆腔淋巴结转移的单因素分析

Table 1. Single-factor analysis of the risk factors affecting pelvic lymph node metastasis

项目	淋巴结转移		统计量	P值
项目	是(n=30)	否(n=71)	统计量	P值
年龄(x±s，岁)	51.13±10.99	54.23±11.46	-1.254^a	0.213
肿瘤直径[M(P₂₅, P₇₅), cm]	4.30(3.68, 5.25)	2.70(1.90, 3.50)	-5.651^b	＜0.001
临床分期[例(%)]			-0.885^b	0.376
ⅠA	0	4(5.6)
ⅠB	18(60.0)	43(60.6)
ⅡA	12(40.0)	24(33.8)
SCC-Ag[M(P₂₅, P₇₅), ng/mL]	6.10(2.15, 7.60)	1.70(1.10, 2.91)	-4.620^b	＜0.001
间质浸润深度[例(%)]			25.345^c	＜0.001
＜1/2	3(10.0)	46(64.8)
≥1/2	27(90.0)	25(35.2)
分化程度[例(%)]			-0.901^b	0.368
Ⅰ	0	1(1.4)
Ⅱ	19(63.3)	50(70.4)
Ⅱ~Ⅲ	5(16.7)	9(12.7)
Ⅲ	6(20.0)	11(15.5)
肿瘤内/外生[例(%)]			0.518^c	0.472
内	24(80.0)	52(73.2)
外	6(20.0)	19(26.8)
脉管浸润[例(%)]			9.151^c	0.002
有	19(63.3)	22(31.0)
无	11(36.7)	49(69.0)
宫旁及阴道壁受累[例(%)]			0.149^c	0.699
是	4(13.3)	6(8.5)
否	26(86.7)	65(91.5)
病理类型[例(%)]			0.821^c	0.365
鳞癌	26(86.7)	67(94.4)
腺癌	4(13.3)	4(5.6)
MRI淋巴结转移[例(%)]			5.892^c	0.015
是	10(33.3)	9(12.7)
否	20(66.7)	62(87.3)
CDK4[例(%)]			-2.284^b	0.022
-	1(3.3)	20(28.2)
+	14(46.7)	28(39.4)
++	9(30.0)	11(15.5)
+++	6(20.0)	12(16.9)
Ki-67[例(%)]			-3.933^b	＜0.001
-	1(3.3)	21(29.6)
+	4(13.3)	21(29.6)
++	11(36.7)	15(21.1)
+++	14(46.7)	14(19.7)
注：^a为t值, ^b为Z值, ^c为χ²值。

下载: 导出CSV

表 2 影响盆腔淋巴结转移的多因素分析

Table 2. Multivariate analysis of factors influencing pelviclymph node metastasi

变量	B	SE	Waldχ²	P值	OR(95% CI)
肿瘤直径	0.730	0.349	4.381	0.036	2.075(1.048~4.109)
SCC-Ag	0.182	0.092	3.912	0.048	1.199(1.002~1.436)
间质浸润深度	1.947	0.866	5.057	0.025	7.007(1.284~38.234)
脉管浸润	0.665	0.719	0.857	0.355	1.945(0.476~7.955)
MRI淋巴结转移	1.200	0.900	1.775	0.183	3.319(0.568~19.389)
CDK4	0.160	0.414	0.149	0.699	1.173(0.521~2.643)
Ki-67	0.872	0.400	4.753	0.029	2.393(1.092~5.243)
注：变量赋值如下，肿瘤直径、SCC-Ag以实际值赋值；脉管浸润，有=1，无=0；MRI淋巴结转移，有=1，无=0；间质浸润深度，＜1/2=1，≥1/2=2；CDK4表达，阴性=1，(+)=2，(++)=3，(+++)=4；Ki-67表达，阴性=1，(+)=2，(++)=3，(+++)=4。

下载: 导出CSV

表 3 各指标及多指标联合对宫颈癌淋巴结转移的预测情况

Table 3. Prediction of lymph node metastasis of cervical cancer by each index and multiple indexes combined

项目	AUC(95% CI)	灵敏度	特异度	阳性预测值(%)	阴性预测值(%)	P值
多指标联合	0.943(0.896~0.989)	0.967	0.873	76.3	98.4	＜0.001
MRI、CDK4与Ki-67联合	0.917(0.864~0.971)	0.967	0.789	65.9	98.2	＜0.001
MRI与SCC-Ag联合	0.890(0.829~0.951)	0.900	0.789	64.3	94.9	＜0.001
MRI	0.857(0.786~0.927)	0.967	0.634	52.7	97.8	＜0.001
SCC-Ag	0.792(0.690~0.894)	0.700	0.845	65.6	87.0	＜0.001
Ki-67	0.740(0.641~0.839)	0.833	0.592	46.3	89.4	＜0.001
CDK4	0.637(0.528~0.747)	0.967	0.282	36.3	95.2	0.030

下载: 导出CSV

参考文献(21)

[1]	李清蓉, 沈文彬. 宫颈癌淋巴结转移MRI特征分析[J]. 影像研究与医学应用, 2022, 6(22): 53-55. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYY202222017.htm LI Q R, SHEN W B. Analysis of MRI features of lymph node metastasis of cervical cancer[J]. Imaging Research and Medical Application, 2022, 6(22): 53-55. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYY202222017.htm
[2]	周满远, 田忠甫, 顾海磊, 等. Ki-67与MRI在宫颈癌根治性手术后宫颈癌淋巴结转移中评价对比[J]. 现代生物医学进展, 2020, 20(21): 4059-4062. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX202021012.htm ZHOU M Y, TIAN Z F, GU H L, et al. Comparison of Ki67 and MRI in cervical lymph node metastasis after radical surgery for cervical cancer[J]. Advances in Modern Biomedicine, 2020, 20(21): 4059-4062. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX202021012.htm
[3]	XIA X, LI D, DU W, et al. Radiomics based on nomogram predict pelvic lymphnode metastasis in early-stage cervical cancer[J]. Diagnostics, 2022, 12: 2446. DOI: 10.3390/diagnostics12102446.
[4]	赵琪, 潘志华, 蒋颖, 等. MRI评估宫颈癌淋巴结转移价值的系统评价[J]. 临床放射学杂志, 2022, 41(8): 1513-1519. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFS202208023.htm ZHAO Q, PAN Z H, JIANG Y, et al. Systematic evaluation of MRI in evaluating lymph node metastasis of cervical cancer[J]Journal of Clinical Radiology, 2022, 41(8): 1513-1519. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFS202208023.htm
[5]	WANG Z, REN C, YANG L, et al. Silencing of circular RNA_0000326 inhibits cervical cancer cell proliferation, migration and invasion by boosting microRNA-338-3p-dependent down-regulation of CDK4[J]. Aging (Albany NY), 2021, 13(6): 9119-9134.
[6]	周游. 宫颈癌组织中Ki-67、SOX9蛋白表达及临床意义[J]. 医药论坛杂志, 2022, 43(22): 103-106. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYX202222028.htm ZHOU Y. The expression and clinical significance of Ki-67 and SOX9 proteins in cervical cancer[J]. Journal of Medical Forum, 2022, 43(22): 103-106. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYX202222028.htm
[7]	李静, 索红燕, 孔为民. 《国际妇产科联盟(FIGO)2018癌症报告: 宫颈癌新分期及诊治指南》解读[J]. 中国临床医生杂志, 2019, 47(6): 646-649. doi: 10.3969/j.issn.2095-8552.2019.06.008 LI J, SUO H Y, KONG W M. Interpretation of FIGO 2018 Cancer Report: New staging and Treatment Guidelines for Cervical cancer[J]. Chinese Journal of Clinical Physicians, 2019, 47(6): 646-649. doi: 10.3969/j.issn.2095-8552.2019.06.008
[8]	杨苗苗, 牛爱琴, 王艳春. SCC-Ag、FIB、VEGF-C与宫颈鳞癌患者盆腔淋巴结转移的关系[J]. 中国卫生工程学, 2022, 21(4): 651-654. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWX202204047.htm YANG M M, NIU A Q, WANG Y C. Relationship between SCC-Ag, FIB, VEGF-C and pelvic lymph node metastasis in patients with cervical squamous cell carcinoma[J]. Chinese Journal of Health Engineering, 2022, 21(4): 651-654. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWX202204047.htm
[9]	郭丽娜, 杜小强, 黄丽玲, 等. 淋巴结平均直径对不伴淋巴结转移宫颈癌患者预后的影响[J]. 现代妇产科进展, 2023, 32(2): 86-89. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202302002.htm GUO L N, DU X Q, HUANG L L, et al. Effect of mean lymph node diameter on prognosis of patients with cervical cancer without lymph node metastasis[J]. Advances in Modern Obstetrics and Gynecology, 2023, 32(2): 86-89. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202302002.htm
[10]	程晓阳, 周旭峰. 宫颈癌患者MRI术前分期诊断率以及盆腔淋巴结转移的诊断价值分析[J]. 临床研究, 2022, 30(9): 132-135. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYN202209039.htm CHENG X Y, ZHOU X F. Preoperative staging rate of MRI and diagnostic value of pelvic lymph node metastasis in patients with cervical cancer[J]. Journal of Clinical Research, 2022, 30(9): 132-135. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYN202209039.htm
[11]	吕加金, 顾濛, 胡晓静, 等. 鳞状细胞癌抗原对宫颈鳞癌淋巴结转移的预测价值[J]. 长治医学院学报, 2022, 36(6): 446-449. https://www.cnki.com.cn/Article/CJFDTOTAL-CZYX202206010.htm LYU J J, GU M, HU X J, et al. Prediction value of squamous cell carcinoma antigen in lymph node metastasis of cervical squamous cell carcinoma[J]. Journal of Changzhi Medical College, 2022, 36(6): 446-449. https://www.cnki.com.cn/Article/CJFDTOTAL-CZYX202206010.htm
[12]	雷月, 朱烨, 李娟, 等. MRI联合鳞状细胞癌抗原在宫颈鳞状细胞癌淋巴结转移的诊断价值[J]. 东南国防医药, 2019, 21(5): 524-526. https://www.cnki.com.cn/Article/CJFDTOTAL-DNGY201905017.htm LEI Y, ZHU Y, LI J, et al. The value of MRI combined with squamous cell carcinoma antigen in the diagnosis of lymph node metastasis of cervical squamous cell carcinoma[J]. Southeast Defense Medicine, 2019, 21(5): 524-526. https://www.cnki.com.cn/Article/CJFDTOTAL-DNGY201905017.htm
[13]	刘梦君. MRI联合SCC检查对预测早期宫颈癌盆腔淋巴结转移的临床意义[D]. 蚌埠: 蚌埠医学院, 2019. LIU M J. Clinical significance of MRI combined with SCC in predicting pelvic lymph node metastasis of early cervical cancer[D]. Bengbu: Bengbu Medical College, 2019.
[14]	赵梦秋, 晋茂生, 刘红丽, 等. MRI联合术前血清学指标及病理特征对早期宫颈癌淋巴结转移的预测价值[J]. 中华全科医学, 2023, 21(2): 199-202, 303. doi: 10.16766/j.cnki.issn.1674-4152.002844 ZHAO M Q, JIN M S, LIU H L, et al. Prognostic value of MRI combined with preoperative serological indexes and pathological features in lymph node metastasis of early cervical cancer[J]. Chinese Journal of General Practice, 2023, 21(2): 199-202, 303. doi: 10.16766/j.cnki.issn.1674-4152.002844
[15]	吕童歆, 巩双铭, 李磊. 细胞周期蛋白依赖性激酶及其在肿瘤治疗中的意义[J]. 生物学教学, 2023, 48(3): 5-8. https://www.cnki.com.cn/Article/CJFDTOTAL-SWJX202303003.htm LYU T X, GONG S M, LI L. Cyclin-dependent kinase and its significance in tumor therapy[J]. Biology Teaching, 2023, 48(3): 5-8. https://www.cnki.com.cn/Article/CJFDTOTAL-SWJX202303003.htm
[16]	YAO S, SUN H. Expression and Clinical Significance of CREPT and CDK4 in Cervical Cancer[J]. Iran J Public Health, 2021, 50(2): 418-420.
[17]	POPIEL-KOPACZYK A, GRZEGRZOLKA J, PIOTROWSKA A, et al. The expression of Testin, Ki-67 and p16 in cervical cancer diagnostics[J]. Curr Issues Mol Biol, 2023, 45: 490-500.
[18]	陈冰, 马彩玲. 宫颈癌患者P53、P16、Ki-67表达、病理特征及预后的意义[J]. 新疆医学, 2021, 51(10): 1101-1107. https://www.cnki.com.cn/Article/CJFDTOTAL-XJYI202110001.htm CHEN B, MA C L. Expression, pathological features and prognostic significance of P53, P16 and Ki-67 in patients with cervical cancer[J]. Xinjiang Medicine, 2021, 51(10): 1101-1107. https://www.cnki.com.cn/Article/CJFDTOTAL-XJYI202110001.htm
[19]	陆天炎, 黄莹莹, 张佳娜. 子宫颈癌患者组织中CK10、Ki-67表达及临床意义[J]. 中国医学创新, 2022, 19(26): 47-51. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYCX202226011.htm LU T, HUANG Y Y, ZHANG J N. Expression of CK10 and Ki-67 in patients with cervical cancer and their clinical significance[J]. Chinese Journal of Medical Innovation, 2022, 19(26): 47-51. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYCX202226011.htm
[20]	罗君花, 张华东, 丁琪. 不同年龄宫颈癌患者Ki67表达及病理特征比较[J]. 实用癌症杂志, 2021, 36(1): 43-45, 56. https://www.cnki.com.cn/Article/CJFDTOTAL-SYAZ202101011.htm LUO J H, ZHANG H D, DING Q. Comparison of Ki67 expression and pathological features in cervical cancer patients of different ages[J]. Journal of Practical Cancer, 2021, 36(1): 43-45, 56. https://www.cnki.com.cn/Article/CJFDTOTAL-SYAZ202101011.htm
[21]	王敏, 邓晶, 谢环. 叶酸受体-α及Ki-67在宫颈癌组织中表达及意义[J]. 中华实用诊断与治疗杂志, 2019, 33(9): 891-894. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD201909015.htm WANG M, DENG J, XIE H. Expression and significance of folate receptor-α and Ki-67 in cervical cancer[J]. Chinese Journal of Practical Diagnosis and Therapy, 2019, 33(9): 891-894. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD201909015.htm